| Sperm proteome maturation in the mouse epididymis S Skerget, MA Rosenow, K Petritis, TL Karr PloS one 10 (11), e0140650, 2015 | 124 | 2015 |
| The Rhesus macaque (Macaca mulatta) sperm proteome S Skerget, M Rosenow, A Polpitiya, K Petritis, S Dorus, TL Karr Molecular & Cellular Proteomics 12 (11), 3052-3067, 2013 | 57 | 2013 |
| Proteomic discovery of diverse immunity molecules in mammalian spermatozoa S Dorus, S Skerget, TL Karr Systems biology in reproductive medicine 58 (4), 218-228, 2012 | 52 | 2012 |
| Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): correlative analyses from MajesTEC-1 D Cortes-Selva, T Casneuf, D Vishwamitra, S Stein, T Perova, S Skerget, ... Blood 140 (Supplement 1), 241-243, 2022 | 32 | 2022 |
| Plasma cell leukemia: a review of the molecular classification, diagnosis, and evidenced-based treatment K Gowin, S Skerget, JJ Keats, J Mikhael, AJ Cowan Leukemia Research 111, 106687, 2021 | 28 | 2021 |
| Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma GSF Anderson, J Ballester-Beltran, G Giotopoulos, JA Guerrero, S Surget, ... Blood, The Journal of the American Society of Hematology 139 (16), 2471-2482, 2022 | 20 | 2022 |
| Genomic basis of multiple myeloma subtypes from the MMRF CoMMpass study S Skerget, D Penaherrera, A Chari, S Jagannath, DS Siegel, R Vij, ... Medrxiv, 2021.08. 02.21261211, 2021 | 16 | 2021 |
| Updated results of talquetamab, a GPRC5D× CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma with prior exposure to t-cell redirecting therapies … AJ Jakubowiak, S Anguille, L Karlin, A Chari, C Schinke, L Rasche, ... Blood 142, 3377, 2023 | 13 | 2023 |
| Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation KA Frerichs, CPM Verkleij, MV Mateos, TG Martin, C Rodriguez, A Nooka, ... Blood advances 8 (1), 194-206, 2024 | 9 | 2024 |
| Identification and characterization of the zebra finch (Taeniopygia guttata) sperm proteome M Rowe, S Skerget, MA Rosenow, TL Karr Journal of Proteomics 193, 192-204, 2019 | 9 | 2019 |
| Integrative analysis of the genomic landscape underlying multiple myeloma at diagnosis: an Mmrf Commpass Analysis A Christofferson, S Nasser, J Aldrich, D Penaherrera, C Legendre, ... Blood 130, 326, 2017 | 7 | 2017 |
| Mechanisms of resistance and relapse with talquetamab in patients with relapsed/refractory multiple myeloma from the phase 1/2 monumenTAL-1 study D Vishwamitra, S Skerget, D Cortes, O Lau, C Davis, T Renaud, J Tolbert, ... Blood 142, 1933, 2023 | 6 | 2023 |
| Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in … P Rodríguez-Otero, CD Schinke, A Chari, B Lipe, N Lavi, L Rasche, ... Journal of Clinical Oncology 41 (16_suppl), 8020-8020, 2023 | 6 | 2023 |
| A molecular analysis of cereblon-related immunomodulatory drug resistance in CoMMpass multiple myeloma patients S Skerget, B Benard, A Christofferson, C Legendre, J Aldrich, S Nasser, ... Blood 130, 1754, 2017 | 5 | 2017 |
| Longitudinal correlative profiles of responders, nonresponders, and those with relapse on treatment with teclistamab in the phase 1/2 MajesTEC-1 study of patients with relapsed … D Vishwamitra, S Skerget, D Cortes, T Perova, O Lau, C Davis, Y Guo, ... Blood 142, 455, 2023 | 4 | 2023 |
| P1506: teclistamab reduces polyclonal immunoglobulin levels and impairs vaccination responses in heavily pretreated MM patients K Frerichs, C Verkleij, MV Mateos, S Zweegman, K Groen, I Kuipers, ... Hemasphere 7 (S3), e5193345, 2023 | 3 | 2023 |
| Multiple myeloma epigenetic programming prognostic of outcome converges with loci reprogrammed in relapsed/refractory disease BG Barwick, S Skerget, JJ Keats, D Auclair, S Lonial, LH Boise, ... Blood 134, 858, 2019 | 3 | 2019 |
| Whole genome DNA methylation analysis of multiple myeloma identifies pervasive hypomethylation and biomarkers of survival BG Barwick, DR Powell, D Penaherrera, S Skerget, JJ Keats, D Auclair, ... Cancer Research 79 (13_Supplement), 839-839, 2019 | 3 | 2019 |
| T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma CPM Verkleij, CA O’Neill, MEC Broekmans, KA Frerichs, WSC Bruins, ... Clinical Cancer Research, OF1-OF17, 2024 | 2 | 2024 |
| Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1 D Cortes-Selva, T Perova, S Skerget, D Vishwamitra, S Stein, ... Blood, 2024 | 2 | 2024 |
Jonathan J KeatsAssistant Professor, Translational Genomics Research Institute在 tgen.org 的电子邮件经过验证
